LLS Community is getting an update! In response to feedback, your support team is working on features to help you stay more engaged and improve functionality and access. Stay tuned for more information coming soon.
Here at The Leukemia & Lymphoma Society (LLS), we applaud every advance for children with blood cancers. Today's reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) expanded the approval of daunorubicin and cytarabine (Vyxeos®) to include treatment of pediatric patients aged one year and older with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). This is a welcome and necessary advancement in...
I was diagnosed with non-Hodgkin lymphoma in mid-2015. It was the most difficult day of my life because I was alone in the USA at this time; I had no friends. I did not speak English even though I was a civil engineer in my country. The hardest of all, my family did not come with me. I have four daughters who I love madly and they love me so much. I felt that I would never seen them again; it was a feeling so hard to describe. My love for them made me decide to be stronger and fight the d...
Health insurance is supposed to protect patients when they need help the most. When it works for patients the way it’s supposed to, it keeps their costs affordable and ensures they can get the life-saving treatment they need. But what do you call health “insurance” that’s not there when you need it most? We call it “substandard” coverage, and LLS just took another major action to sound the alarm on this problem. Thirty patient organizations, led by LLS, just published the ...
Diffuse Large B-Cell Non-Hodgkin Lymphoma: Diagnosis, Treatment, and Nutrition A Virtual Education Program (Lower Plains Region) April 6, 2021 6:00pm – 7:30pm (CT) https://www.lls.org/events/dlbcl Adolescent and Young Adult Survivorship: Special Considerations A Virtual Education Program (NJ-Metro NY-CT-HV Regions) April 7, 2021 4:00pm – 6:00pm (ET) https://www.lls.org/events/Adolescent-and-Young-Adult-Survivorship Young Adult Cancer Survivorship A Virtual Education Program...
Chimeric Antigen Receptor (CAR) T cell-therapy is on a roll. Today marks the seventh approval of CAR T therapy since the first approval in 2017. While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. This approval comes on the h...
In honor of Myeloma Awareness Month in March, The Leukemia & Lymphoma Society (LLS) is shining a light on how we champion myeloma cures and care. For Jennifer Flowers, who was diagnosed with multiple myeloma in 2008, our free education and support services and the powerful sense of community at our Light The Night events have made all the difference. Motivated to help other blood cancer patients and families, Jennifer has held several volunteer roles with LLS, including serving as an Hono...
If you are a blood cancer patient, survivor, caregiver in the United States, or know someone who is, The Leukemia & Lymphoma Society (LLS) needs your help with a research initiative aimed at learning more about COVID-19 and blood cancer patients. We invite patients and survivors to sign up for The LLS National Patient Registry to help shape discoveries that can improve the quality of life and care for people living with blood cancers. About the Registry The LLS National Patient R...
Sharon Cohan, LCSW and Information Specialist for The Leukemia & Lymphoma Society, states, “One of the biggest myths is that everyone diagnosed with cancer will be diagnosed with depression. Only 15-25% of cancer patients get diagnosed with depression. Everyone will have a period of adjustment with some depression and anxiety which usually improves with time and education.”-from Choosing Therapy article Cancer & Depression: Connection, Risks & Treatment. LLS Informatio...
The U.S. Food and Drug Administration (FDA) today approved the CAR T-cell treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphoma (FL) that has returned or worsened despite earlier treatment. FL is the most common slow-growing non-Hodgkin’s lymphoma and while the disease can generally be managed, reoccurrence is common. LLS was among the first to invest in CAR T in the 1990’s. Today, the therapy has rapidly become a mainstay of cancer care. LLS supported cl...
In honor of International Women’s Day on March 8, The Leukemia & Lymphoma Society (LLS) is celebrating women scientists, physicians, philanthropic leaders, social workers, nurses, staff, and supporters at the front lines of the fight against blood cancer. From bolstering the early careers of researchers to helping scientists accelerate their discoveries from the lab to clinical trials, LLS is dedicated to supporting and recognizing women in science and all those who are advancing our mi...
